| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the Fédération de Génétique, Ophthalmology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; the 2 Ophthalmology Department, Hôpital Lariboisière, Paris, France; the 3 Biostatistics Department, Hôpital Necker-Enfantes Malades, Paris, France; the 4 Ophthalmology Department, Hôpital La Croix Rousse, Lyon, France; 5 the Ophthalmology Department, University Hospital Center, Clermont-Ferrand, France; the 6 Genetics Laboratory, Hôpital Edouard Herriot, Lyon, France; the 7 Institut National pour la Santé et Recherche Médicale U383, Hôpital Necker-Enfants Malades, Paris, France; the 8 Ophthalmology Department, University Hospital Center, Necker, Paris, France; and 10 Laboratory of Oncogenetics, Ecole Pratique des Hautes Etudes, Le Kremlin Bicêtre and Department of Nephrology, Hôpital Necker-Enfants Malades, Paris, France.
PURPOSE. To assess the natural history of retinal manifestations in von Hippel-Lindau (VHL) disease and to study the genotype–phenotype correlation.
METHODS. Data concerning 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations were extracted from the French VHL database. A retrospective study was performed by questionnaire. Patients were classified into three visual morbidity groups. Molecular analysis of the VHL gene was performed in 196 patients.
RESULTS. The mean age of ocular manifestations detection was 24.8 years. In half of the cases, the ocular manifestations revealed the disease. Half of the cases had bilateral involvement. Visual morbidity was significantly associated with the retinal hemangioblastoma count but not with other ocular or general characteristics. One third of the patients were classified in the worst visual morbidity group at the end of follow-up. Mutations were detected in 81% of patients with retinal hemangioblastomas and in 71% of patients without retinal involvement. Using a Poisson model and a marginal approach, the number of hemangioblastomas, age-adjusted, was 2.1 times higher in patients who had a substitution than in patients with a truncation (95% CI, 1.05–4.44; P < 0.05).
CONCLUSIONS. Visual loss remains one of the major complications of VHL disease, confirming the importance of early ophthalmologic screening. Visual morbidity was not related to the type of extraocular manifestation but appeared to be related to the type of germline mutation. However, only further genetic and clinical studies in a larger series of patients will clearly determine the genotype–phenotype relationship.
This article has been cited by other articles:
|
|
 |
|
  M. Feucht, L. Kluwe, V.-F. Mautner, and G. Richard Correlation of Nonsense and Frameshift Mutations With Severity of Retinal Abnormalities in Neurofibromatosis 2 Arch Ophthalmol, October 1, 2008; 126(10): 1376 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Wong, E. Agron, H. R. Coleman, G. F. Reed, K. Csaky, J. Peterson, G. Glenn, W. M. Linehan, P. Albert, and E. Y. Chew Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomatosis Arch Ophthalmol, February 1, 2007; 125(2): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M Knapp, G Woodruff, and F Roberts Ophthalmic pathology of genotypically confirmed von Hippel Lindau disease type 1 Br. J. Ophthalmol., February 1, 2006; 90(2): 242 - 243. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
